Welcome!

News Feed Item

BD Announces Results For 2014 First Fiscal Quarter

-- Raises the bottom end of full fiscal year 2014 revenue and earnings ranges for guidance.

FRANKLIN LAKES, N.J., Feb. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the first fiscal quarter ended December 31, 2013, representing an increase of 6.0 percent from the prior-year period, or 6.7 percent on a foreign currency-neutral basis. Revenue growth was aided, in part, by favorable timing of orders in the BD Medical and BD Diagnostics segments.

"Fiscal year 2014 is off to a strong start," said Vincent A. Forlenza, Chairman, CEO and President. "Our revenue and earnings growth exceeded our expectations and we have continuing confidence that we have built a solid foundation for future growth. Accordingly, we are raising the bottom end of our previous revenue and earnings ranges for our full fiscal year guidance."

First Quarter Earnings
Reported diluted earnings per share from continuing operations for the first quarter were $1.37 compared with $1.35 in the prior-year period, representing a 1.5 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the first quarter increased by 8.1 percent. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were $1.42, or an increase of 11.9 percent.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.06 billion, representing an increase of 8.2 percent compared with the prior-year period, or an increase of 8.6 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Medical Surgical Systems and Diabetes Care units and solid sales in the Pharmaceutical Systems unit. Both the Medical Surgical and Pharmaceutical Systems units also benefitted from favorable timing of orders.

In the BD Diagnostics segment, worldwide revenues for the quarter were $672 million, representing an increase of 3.1 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. The segment's growth was driven by international expansion in both the Preanalytical Systems and Diagnostic Systems business units. Diagnostic systems growth was also aided, in part, from a timing of flu orders.

In the BD Biosciences segment, worldwide revenues for the quarter were $279 million, representing an increase of 5.4 percent compared with the prior-year period, or an increase of 5.7 percent on a foreign currency-neutral basis. The segment's growth was driven by continued strength in emerging markets, clinical reagents sales and solid instrument placements in both the U.S. and Western Europe.

Geographic Results
First quarter revenues in the U.S. of $849 million represent an increase of 2.3 percent over the prior-year period. Revenues outside of the U.S. were $1.17 billion, representing an increase of 8.9 percent compared with the prior-year period, or an increase of 10.0 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products in addition to solid growth in Western Europe.

Fiscal 2014 Outlook for Full Year
The Company estimates that reported and currency-neutral revenues for the full fiscal year 2014 will increase 4.5 to 5.0 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2014 to be between $6.19 and $6.22, which represents growth of 6.5 to 7.0 percent over 2013 adjusted diluted earnings per share of $5.81.  On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 9.0 to 9.5 percent, or 9.5 to 10.0 percent excluding the incremental impact of the medical device tax.  The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in fiscal year 2014.

Conference Call Information
A conference call regarding BD's first quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, February 4th, 2014.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, February 11, 2014, confirmation number 31318159.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying whole-dollar amounts.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Alyssa J. Zeff, Corporate Communications – 201-847-4358

 

BECTON DICKINSON AND COMPANY


CONSOLIDATED INCOME STATEMENTS


(Unaudited; Amounts in millions, except share and per share data)











Three Months Ended December 31,



2013


2012


% Change










REVENUES

$

2,015

$

1,900


6.0










Cost of products sold


980


894


9.6


Selling and administrative 


531


496


7.1


Research and development


126


118


6.4


TOTAL OPERATING COSTS








     AND EXPENSES


1,637


1,508


8.5










OPERATING INCOME


378


392


(3.6)










Interest income


14


8


75.7


Interest expense


(34)


(35)


(4.3)


Other income, net


1


1


(14.0)










INCOME FROM CONTINUING OPERATIONS BEFORE








     INCOME TAXES


359


366


(1.9)










Income tax provision


88


95


(8.3)










INCOME FROM CONTINUING OPERATIONS


271


270


0.4










INCOME FROM DISCONTINUED OPERATIONS








   NET OF INCOME TAX PROVISION OF








   $0 AND $216, RESPECTIVELY


-


355


        NM 










NET INCOME

$

271

$

625


(56.6)










EARNINGS PER SHARE
















Basic:








Income from continuing operations

$

1.40

$

1.38


1.4


Income from discontinued operations

$

-

$

1.81


        NM 


Net income 

$

1.40

$

3.18


(56.0)










Diluted:








Income from continuing operations

$

1.37

$

1.35


1.5


Income from discontinued operations

$

-

$

1.78


        NM 


Net income 

$

1.37

$

3.13


(56.2)


















AVERAGE SHARES OUTSTANDING (in thousands)
















     Basic


194,203


196,427




     Diluted


198,110


199,570












NM - Not Meaningful








 

BECTON DICKINSON AND COMPANY


SUPPLEMENTAL REVENUE INFORMATION


REVENUES BY SEGMENT AND GEOGRAPHIC AREA


(Unaudited; Amounts in millions)











Three Months Ended December 31,



2013


2012


% Change










BD MEDICAL








   United States

$

441

$

425


3.8


   International


622


558


11.5


TOTAL

$

1,064

$

983


8.2










BD DIAGNOSTICS








   United States

$

321

$

321


0.1


   International


351


331


6.0


TOTAL

$

672

$

652


3.1










BD BIOSCIENCES








   United States

$

87

$

84


3.3


   International


192


181


6.3


TOTAL

$

279

$

265


5.4










TOTAL REVENUES








   United States

$

849

$

830


2.3


   International


1,166


1,070


8.9


TOTAL

$

2,015

$

1,900


6.0


 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31,

(Unaudited; Amounts in millions)









United States



2013


2012


 % Change 








BD MEDICAL







   Medical Surgical Systems

$

262

$

249


5.3

   Diabetes Care


122


112


8.4

   Pharmaceutical Systems


57


64


(10.4)

TOTAL

$

441

$

425


3.8








BD DIAGNOSTICS







   Preanalytical Systems

$

171

$

167


2.7

   Diagnostic Systems


149


154


(2.7)

TOTAL

$

321

$

321


0.1








BD BIOSCIENCES

$

87

$

84


3.3








TOTAL UNITED STATES

$

849

$

830


2.3

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













International







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL











   Medical Surgical Systems

$

317

$

287


10.4


12.4


(2.0)

   Diabetes Care


142


130


8.7


11.5


(2.8)

   Pharmaceutical Systems


164


141


16.4


12.6


3.8

TOTAL

$

622

$

558


11.5


12.2


(0.7)












BD DIAGNOSTICS











   Preanalytical Systems

$

176

$

168


4.8


6.1


(1.3)

   Diagnostic Systems


175


164


7.2


10.2


(3.0)

TOTAL

$

351

$

331


6.0


8.1


(2.1)












BD BIOSCIENCES

$

192

$

181


6.3


6.8


(0.5)












TOTAL INTERNATIONAL

$

1,166

$

1,070


8.9


10.0


(1.1)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended December 31, (continued)

(Unaudited; Amounts in millions)













Total







 % Change 



2013


2012


 Reported 


FXN


FX Impact












BD MEDICAL 











   Medical Surgical Systems

$

579

$

536


8.0


9.1


(1.1)

   Diabetes Care


264


243


8.6


10.1


(1.5)

   Pharmaceutical Systems


221


205


8.0


5.5


2.5

TOTAL

$

1,064

$

983


8.2


8.6


(0.4)












BD DIAGNOSTICS











   Preanalytical Systems

$

347

$

335


3.7


4.4


(0.7)

   Diagnostic Systems


325


317


2.4


3.9


(1.5)

TOTAL

$

672

$

652


3.1


4.2


(1.1)












BD BIOSCIENCES

$

279

$

265


5.4


5.7


(0.3)












TOTAL REVENUES

$

2,015

$

1,900


6.0


6.7


(0.7)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)













Three Months Ended December 31,







 % Change 



2013


2012


 Reported 


FXN


FX Impact












TOTAL SAFETY REVENUES











   United States

$

315

$

291


8.1


8.1


-

   International


242


220


10.1


12.0


(1.9)

TOTAL

$

557

$

511


9.0


9.8


(0.8)












BY SEGMENT











   BD Medical

$

285

$

252


13.0


14.0


(1.0)

   BD Diagnostics


272


259


5.0


5.7


(0.7)

TOTAL

$

557

$

511


9.0


9.8


(0.8)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

















Three Months Ended December 31,



2013


2012


Growth


Foreign Currency Translation


Foreign Currency Neutral Change


Growth %


Foreign Currency Neutral Growth %
















Reported Diluted Earnings per Share from Continuing Operations

$

1.37

$

1.35

$

0.02

$

(0.09)

$

0.11


1.5%


8.1%
















Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act
($14 million or $9 million after-tax)


0.05


0.00


























Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax

$

1.42

$

1.35

$

0.07

$

(0.09)

$

0.16


5.2%


11.9%

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Outlook Reconciliation










Reported







Basis


FX Impact


FXN Basis








Revenues - Full Year 2014 estimated growth


4.5% - 5.0%


0.0%


4.5% - 5.0%













































Full Year


Full Year





2014


2013


% Increase



(estimated)





Reported Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

4.67


NM








Pending Litigation Settlement (1)




0.07










Verdict Charge (2)




1.06










Pension Settlement Charge (3)




0.02










Adjusted Fully Diluted Earnings per Share 







from Continuing Operations

$

6.19 - 6.22

$

5.81


6.5% - 7.0%








FX Impact






(2.5%)








Adjusted FXN Growth






9.0% - 9.5%








Medical Device Excise Tax Impact (4)






(0.5%)








Adjusted FXN Growth (excluding the medical device excise tax)






9.5% - 10.0%

 

(1) Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.












(2) Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI.












(3) Represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.












(4) Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act).























NM - Not Meaningful











FXN = Foreign Currency Neutral











 

SOURCE BD (Becton, Dickinson and Company)

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
On Dice.com, the number of job postings asking for skill in Amazon Web Services increased 76 percent between June 2015 and June 2016. Salesforce.com saw its own skill mentions increase 37 percent, while DevOps and Cloud rose 35 percent and 28 percent, respectively. Even as they expand their presence in the cloud, companies are also looking for tech professionals who can manage projects, crunch data, and figure out how to make systems run more autonomously. Mentions of ‘data science’ as a skill ...
Cloud analytics is dramatically altering business intelligence. Some businesses will capitalize on these promising new technologies and gain key insights that’ll help them gain competitive advantage. And others won’t. Whether you’re a business leader, an IT manager, or an analyst, we want to help you and the people you need to influence with a free copy of “Cloud Analytics for Dummies,” the essential guide to this explosive new space for business intelligence.
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effi...